You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

My Incruse Ellipta medicine

These pages are specifically for patients who have been prescribed Incruse Ellipta. If you are not a patient please return to the public website.

What is Incruse Ellipta?

Incruse Ellipta contains an active substance called umeclidinium bromide, which belongs to a group of medicines called bronchodilators. 1

How does Incruse Ellipta work?

This medicine is used to treat chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term condition in which the airways and air-sacs in the lungs gradually become blocked or damaged, leading to breathing difficulties that slowly get worse. Difficulties in breathing is added to by tightening of the muscles around the airways, which narrows the airways and so restricts the flow of air. 1

This medicine blocks the tightening of these muscles, making it easier for air to get in and out of the lungs. When used regularly, it can help control your breathing difficulties and reduce the effects of COPD on your everyday life. 1

Incruse Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing. If you get this sort of attack you must use a quick-acting reliever inhaler (such as salbutamol). 1

How do I take Incruse Ellipta?

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure 1. For instruction about how to use the Ellipta inhaler, please refer to the Ellipta guide.

The recommended dose is one inhalation every day at the same time of day. You only need to inhale once a day because the effect of this medicine lasts for 24 hours. 1 Don't use more than your doctor tells you to use.

Use Incruse Ellipta regularly

It is very important that you use Incruse every day, as instructed by your doctor. This will help to keep you free of symptoms throughout the day and night. 1

Do not use Incruse Ellipta to relieve a sudden attack of breathlessness or wheezing. If you get this sort of attack you must use a quick-acting reliever inhaler (such as salbutamol). 1

If your symptoms do not improve

If your COPD symptoms (breathlessness, wheezing, cough) do not improve or get worse, or if you are using your quick-acting inhaler more often: contact your doctor as soon as possible.

If you use more Incruse Ellipta than you should

If you accidentally take too much of this medicine, contact your doctor or pharmacist for advice immediately as you may need medical attention. If possible, show them the inhaler, the package or this leaflet. You may notice that your heart is beating faster than usual, you have visual disturbances or have a dry mouth.

If you forget to take Incruse Ellipta

Don’t take an extra dose to make up for a missed dose. Just take your next dose at the usual time.
If you become wheezy or breathless, use your quick-acting inhaler (such as salbutamol), then seek medical advice.

If you stop using Incruse Ellipta

Use this medicine for as long as your doctor recommends. It will only be effective as long as you are using it. Don’t stop unless your doctor advises you to, even if you feel better, as your symptoms may get worse.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.


  1. Incruse Ellipta 55mcg patient information leaflet

INCRUSE Ellipta was developed in collaboration with INNOVIVA Inc.


This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting side effects you may get.

If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via HPRA Pharmacovigilance, Website: By reporting side effects you can help provide more information on the safety of this medicine.

Incruse Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies